story of the week
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in Individuals With Overweight/Obesity but Without Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes Care
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
Diabetes Care 2024 Jun 22;[EPub Ahead of Print], I Lingvay, J Deanfield, SE Kahn, PE Weeke, H Toplak, BM Scirica, L Rydén, N Rathor, J Plutzky, C Morales, AM Lincoff, M Lehrke, OK Jeppesen, G Gajos, HM Colhoun, B Cariou, D RyanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.